ARLG
Antibacterial Resistance Leadership Group

May 2022
Q2 Newsletter

Welcome to the ARLG Newsletter! Here, you will receive important updates from ARLG regarding recent events, grants, publications, and the committees that help us work toward our mission: to prioritize, design, and execute clinical research that will impact the prevention, diagnosis, and treatment of infections caused by antibiotic-resistant bacteria.

Get Involved with ARLG

ARLG continuously accepts proposals for clinical studies designed to prevent, diagnose, treat, or eradicate antibiotic-resistant bacterial pathogens. We also award grants and fellowships to qualified investigators. If you are interested in getting involved with ARLG, apply now or contact us for more information.

Submit a Proposal **Contact Us**

News

Robin Patel to Receive 2022 Hamao Umezawa Memorial Award

The International Society of Antimicrobial Chemotherapy (ISAC) announced it has selected Robin Patel to receive the 2022 Hamao Umezawa Memorial Award (HUMA). Dr. Patel serves as ARLG's Laboratory Center Director and is the Director of the Infectious Diseases Research Laboratory at the Mayo Clinic.

Dr. Patel's work focuses on developing improved diagnostic approaches to combat antibacterial resistance, researching the mechanisms of biofilm formation, and designing and conducting studies for new antibacterial treatment options.

Learn more

Robert Bonomo Named Director of VA SHIELD Coordinating Center

The U.S. Department of Veterans Affairs (VA) selected Robert Bonomo as the Director of the Coordinating Center for the VA Science and Health Initiative to Combat Infectious and Life-Threatening Diseases (VA SHIELD), a cental biospecimen and data repository.

Dr. Bonomo is Chief of the Medical Service and Director of the Geriatric Research Education and Clinical Center (GRECC) at the Cleveland VA Medical Center as well as a member of the ARLG Laboratory Center Consortium Team. His work in antibacterial resistance includes research on the mechanistic basis of resistance to beta-lactam antibiotics and beta-lactamase inhibitors, the molecular epidemiology of multidrug resistant Gram-negative bacteria, and the implementation of molecular diagnostics in clinical care of patients with infectious disease.

Read More

Melinda Pettigrew Named YSPH Interim Dean

The Yale School of Public Health (YSPH) announced that Melinda Pettigrew will serve as the interim Dean of the school beginning July 1. Currently, she is the Anna M. R. Lauder Professor of Epidemiology (Microbial Diseases) and serves as the deputy dean of YSPH. Dr. Pettigrew is the Chair of the ARLG Diversity Working Group and a member of the Laboratory Center Consortium Team.

Read More

CRACKLE II Study Summary Now Available!

A lay summary of results has been posted for the Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE-2) study.

The CRACKLE-2 study investigated types of carbapenem-resistant Enterobacteriaceae (CRE). CRE is a family of bacteria that resists treatment by a class of antibiotics called carbapenems. The World Health Organization lists CRE as one of the top three drug-resistant pathogens and recognizes CRE as a threat

to global public health. The goal of the study was to learn about patients infected with CRE, understand and describe the different types of CRE, and learn how each type affected different patient populations.



Read More

Events

David van Duin to Present at COMBACTE GA

The 2022 COMBACTE General Assembly will take place in Lisbon, Portugal May 30 – 31.

The agenda promises two full days of interesting updates including a presentation from David van Duin about ARLG's Multi-Drug Resistant Organism (MDRO) Network.

View the full event agenda here.

Learn more

Don't Miss Post-ECCMID Day and 2022 On-Demand Content

This year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) featured an exciting array of clinical microbiology and international infectious diseases experts presenting their latest findings.

If you missed any sessions, you're still in luck. Your registration includes access to on-demand content until July 26, 2022.To help you plan, we've added some highlighted presentations and speakers to our website.

Speaking of great content, don't forget to mark your calendars for May 19, 2022. This year's event includes a Post-ECCMID online learning day on the topic of Antimicrobial Resistance and Stewardship. The event is free for ECCMID registrants.

View the Post-ECCMID Programme

Plan for ECCMID 2022 On-Demand

ARLG Grand Rounds 2022

Tune in for ARLG's 2022 upcoming Grand Round Series. This year will feature an exciting variety of speakers and topics. Don't miss the next event:

Date	Topic	Speaker
August 5, 2022	ARLG FAST Trial	Ritu Banerjee, MD, PhD Professor, Pediatric Infectious Diseases Director, Antibiotic Stewardship Program Vanderbilt University Medical Center

You can check out ARLG's event page for ongoing updates about each session and how to attend.

Learn more

Study Milestones

View recent ARLG study updates.

GENO-SMART	**GENO**mics, **S**usceptibility, Clinical Epidemiology and **M**etagenomics of **A**ntibiotic **R**esistance **T**ool (GENO-SMART)	Preparing Proof of Concept Platform Launch
MDRO:SHREC	**S**tudy of **H**ighly **R**esistant **E**scherichia **c**oli (SHREC)	Analysis Complete Manuscript in Progress
PHAGE	Study of the Safety and Microbiological Activity of Bacterio**PHAGE**s in Persons with Cystic Fibrosis Colonized with *Pseudomonas aeruginosa*	Site Start-up
STEP FMT	**S**train **T**emporal **E**ngraftment and **P**ersistence after **F**ecal **M**icrobiota **T**ransplantation	Planning

Go to the ARLG Studies page for more milestones and updates!

Learn More

Recent Publications

View the following recent ARLG publications.

Iovleva A, Mustapha MM, Griffith MP, Komarow L, Luterbach C, Cober E, Richter SS, Arias CA, Jacob JT, Salata RA, Satlin MJ, Wong D, Bonomo RA, van Duin D, Cooper VS, Tyne DV, Doi Y. Carbapenem-Resistant Acinetobacter baumannii in US hospitals: diversification of circulating lineages and antimicrobial resistance. mBio. 2022 Mar 21;e0275921. doi: 10.1128/mbio.02759-21. Online ahead of print.

Lodise TP, Scheetz M, Carreno JJ, Chambers H, Fowler V Jr., Holland HL; on behalf of the Antibacterial Resistance Leadership Group. Associations between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients with MRSA Bloodstream Infections. Open Forum Infect Dis. 2022 Jan 22;9(2):ofab651. doi: 10.1093/ofid/ofab651. eCollection 2022 Feb.

Howard-Anderson J, Davis M, page AM, Bower CW, Smith G, Jacob JT, Andersson DI, Weiss DS, Satola SW. Prevalence of Colistin Heteroresistance in Carbapenem-Resistant Pseudomonas aeruginosa and Association with Clinical Outcomes in Patients: An Observational Study. J Antimicrob Chemother. 2022 Feb 23;77(3):793-798. doi: 10.1093/jac/dkab461.

Williams DJ, Creech CB, Walter EB, Martin JM, Gerber JS, Newland JG, Howard L, Hofto ME, Staat M, Oler RE, Tuyishimire B, Conrad TM, Lee M, Ghazaryan V, Knisely J, Pettigrew MM, Fowler VG, Chambers HF, Zaoutis TE, Evans S, Huskins WC; and the DMID 14-0079 Study Team. Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial. JAMA Pediatr. 2022 Mar 1;176(3):253-261. doi: 10.1001/jamapediatrics.2021.5547.

Shropshire WC, Dinh AQ, Earley M, Komarow L, Panesso D, Rydell K, Gomez-Villegas SI, Miao H, Hill C, Chen L, Patel R, Fries BC, Abbo L, Cober E, Revolinski S, Luterbach CL, Chambers H, Fowler VG, Bonomo RA, Shelburne SA, Kreiswirth BN, van Duin D, Hanson BM, Arias CA. Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX. mBio. 2022 Mar 31;e0049722. doi: 10.1128/mbio.00497-22. Online ahead of print.

Howard-Anderson J, Earley M, Komarow L, Abbo L, Anderson DJ, Gallagher JC, Grant M, Kim A, Bonomo RA, van Duin D, Munoz-Price LS, Jacob JT; The Antibacterial Resistance Leadership Group. Poor outcomes in both infection and colonization with carbapenem-resistant Enterobacterales. Infect Control Hosp Epidemiol. 2022 Feb 2;1-7. doi: 10.1017/ice.2022.4. Online ahead of print.

Pettigrew MM, Kwon J, Gent JF, Kong Y, Wade M, Williams DJ, Creech CB, Evans S, Pan Q, Walter EB, Martin JM, Gerber JS, Newland JG, Howard L, Hofto ME, Staat MA, Fowler VG, Chambers HF, Huskins WC; on behalf of the Antibacterial Leadership Resistance Group. Comparison of the respiratory resistome in children receiving short vs. standard course treatment for community acquired pneumonia. mBio. 2022 Mar 24;e0019522. doi: 10.1128/mbio.00195-22. Online ahead of print.

Patel R, Polage CR, Dien Bard J, May L, Lee F, Fabre V, Hayden MK, Doernberg SDB, Haake DA, Trautner BW, Grigoryan L, Tsalik EL, Hanson KE; on behalf of the Antibacterial Resistance Leadership Group and the Infectious Diseases Society of America. Envisioning Future Urinary Tract Infection Diagnostics. Clin Infect Dis. 2022 Apr 9;74(7):1284-1292. doi: 10.1093/cid/ciab749.

Kwon J, Kong Y, Wade M, Williams DJ, Creech CB, Evans S, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Fowler VG, Chambers HF, Huskins WC, Pettigrew MM; on behalf of the Antibacterial Resistance Leadership Group. Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia. J Infect Dis. 2022 Mar 6;jiac082. doi: 10.1093/infdis/jiac082. Online ahead of print.

Thaden J, Tamma P, Pan Q, Doi Y, Daneman N. Survey of Infectious Diseases Providers Reveals Variability in Duration of Antibiotic Therapy for the Treatment of Gram-Negative Bloodstream Infections. JAC Antimicrob Resist. 2022 Feb 9;4(1):dlac005. doi: 10.1093/jacamr/dlac005. eCollection 2022 Mar.